Introduction
Phesgo is a prescription medication that contains the active ingredients Pertuzumab and Trastuzumab. Pertuzumab and Trastuzumab are both targeted therapies used in the treatment of HER2-positive breast cancer.
Uses
Phesgo is indicated for the treatment of HER2-positive breast cancer in patients who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is typically used in combination with other anti-cancer medications.
Dosage and Administration
Phesgo is administered as an intravenous infusion and should be given under the supervision of a healthcare professional experienced in the administration of chemotherapy. The recommended dosage and treatment schedule may vary depending on individual patient factors and treatment response. Follow the specific instructions provided by your healthcare provider.
Mechanism of Action
Pertuzumab and Trastuzumab, the active ingredients in Phesgo, are monoclonal antibodies that work by targeting and blocking the HER2 receptor, which is overexpressed in HER2-positive breast cancer cells. By inhibiting HER2 signaling, these medications help to slow down the growth of cancer cells and may lead to tumor shrinkage.
Side Effects
Common side effects of Phesgo may include fatigue, diarrhea, nausea, vomiting, hair loss, and rash. Note that not all patients will experience these side effects, and the severity may vary. If any of these side effects persist or worsen. Inform your healthcare provider.
Serious side effects may also occur with Phesgo. These can include heart problems, lung problems, infusion reactions, and decreased blood cell counts. Seek immediate medical attention if you experience symptoms such as chest pain, shortness of breath, persistent cough, allergic reactions, or signs of infection (such as fever, chills, or sore throat).
Drug Interactions
Phesgo may interact with certain medications, including other chemotherapy drugs or targeted therapies. Inform your healthcare provider about all medications, supplements, and herbal products you are taking before starting treatment with Phesgo. Your healthcare provider will be able to provide guidance on any potential drug interactions.
Precautions
Before using Phesgo, inform your healthcare provider about any pre-existing medical conditions, including heart or lung problems. This medication may not be suitable for everyone, and your healthcare provider will assess the potential risks and benefits before initiating treatment.
Phesgo should not be used during pregnancy, as it may cause harm to the unborn baby. Effective contraception should be used during treatment and for a certain period of time after the last dose. Discuss family planning options with your healthcare provider.
Storage
Patient Tips
- Follow the recommended treatment schedule and dosage instructions provided by your healthcare provider.
- Report any persistent or bothersome side effects to your healthcare provider.
- Stay well-hydrated and follow any dietary recommendations provided by your healthcare provider.
- Use effective contraception during treatment and discuss family planning options with your healthcare provider.
- Keep all appointments for follow-up visits and laboratory tests as scheduled.
- Store the medication properly in the refrigerator and avoid freezing.
- If you have any questions or concerns about your treatment, do not hesitate to reach out to your healthcare provider for clarification.
Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.
References
- Trastuzumab: a medicine to treat some types of cancer (NHS UK) [Accessed 29 Jun. 2024] (online) Available at:
- Perjeta 420 mg Concentrate for Solution for Infusion (Health Professionals SmPC) Available at:
- Pertuzumab (Drugs.com) [Accessed 9 Jun. 2024] (online) Available at:
- pertuzumab 1,200 mg-trastuzumab 600 mg-hyaluron-zzxf/15 ml subcut soln (RX) [Accessed 3 Jun. 2024] (online) Available at:
- Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection (MedlinePlus) [Accessed 20 Jun. 2024] (online) Available at:
- von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. [Accessed 12 Jun. 2024] Available at:
Reviews
There are no reviews yet.